The creation of this antidote is a big deal that can affect the lives of millions of people around the world.
A new generation of anticoagulants on the market, the so called Factor Xa inhibitors have shown substantial advantages over current standard therapies, such as the warfarin and enoxaparin.
However, physicians need a rapid reversal agent for patients who start bleeding or require urgent surgery. As it stands, no such antidote exists.
Although bleeding events occur infrequently (1-4 percent in clinical studies), the absolute number globally is really...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: